Pyridines and derivatives
7-Fluoro-2-methylquinoline 98.0+%, TCI America™
CAS: 1128-74-1 Molecular Formula: C10H8FN Molecular Weight (g/mol): 161.179 InChI Key: AYSKNDXTWPNRKG-UHFFFAOYSA-N Synonym: 7-Fluoroquinaldine PubChem CID: 2779075 IUPAC Name: 7-fluoro-2-methylquinoline SMILES: CC1=NC2=C(C=C1)C=CC(=C2)F
2,2'-Bipyridine-6,6'-dicarboxylic Acid 98.0+%, TCI America™
CAS: 4479-74-7 Molecular Formula: C12H8N2O4 Molecular Weight (g/mol): 244.21 MDL Number: MFCD11042476 InChI Key: DASAXWLMIWDYLQ-UHFFFAOYSA-N PubChem CID: 9959961 IUPAC Name: [2,2'-bipyridine]-6,6'-dicarboxylic acid SMILES: OC(=O)C1=CC=CC(=N1)C1=NC(=CC=C1)C(O)=O
Apexbio Technology LLC Vortioxetine 508233-74-7 25mg
Vortioxetine (CAS 508233-74-7) is a multimodal antidepressant currently under investigation for the treatment of depression It demonstrates high affinity for recombinant human serotonin receptors including 5-HT1A (Ki 15 nM) 5-HT1B (Ki 33 nM) 5-HT3A (Ki 3 7 nM) 5-HT7 (Ki 19 nM) noradrenergic 1 receptors (Ki 46 nM) and the serotonin transporter SERT (Ki 1 6 nM) Vortioxetine acts as an antagonist at 5-HT3A and 5-HT7 partial agonist at 5-HT1B agonist at 5-HT1A and exhibits potent SERT inhibition In vivo studies show that short-term administration increases extracellular 5-HT in rat brain Vortioxetine s multimodal activity makes it a valuable tool for research into serotonergic modulation and antidepressant mechanisms
Apexbio Technology LLC Vortioxetine 508233-74-7 5mg
Vortioxetine (CAS 508233-74-7) is a multimodal antidepressant currently under investigation for the treatment of depression It demonstrates high affinity for recombinant human serotonin receptors including 5-HT1A (Ki 15 nM) 5-HT1B (Ki 33 nM) 5-HT3A (Ki 3 7 nM) 5-HT7 (Ki 19 nM) noradrenergic 1 receptors (Ki 46 nM) and the serotonin transporter SERT (Ki 1 6 nM) Vortioxetine acts as an antagonist at 5-HT3A and 5-HT7 partial agonist at 5-HT1B agonist at 5-HT1A and exhibits potent SERT inhibition In vivo studies show that short-term administration increases extracellular 5-HT in rat brain Vortioxetine s multimodal activity makes it a valuable tool for research into serotonergic modulation and antidepressant mechanisms
Apexbio Technology LLC Vortioxetine 508233-74-7 100mg
Vortioxetine (CAS 508233-74-7) is a multimodal antidepressant currently under investigation for the treatment of depression It demonstrates high affinity for recombinant human serotonin receptors including 5-HT1A (Ki 15 nM) 5-HT1B (Ki 33 nM) 5-HT3A (Ki 3 7 nM) 5-HT7 (Ki 19 nM) noradrenergic 1 receptors (Ki 46 nM) and the serotonin transporter SERT (Ki 1 6 nM) Vortioxetine acts as an antagonist at 5-HT3A and 5-HT7 partial agonist at 5-HT1B agonist at 5-HT1A and exhibits potent SERT inhibition In vivo studies show that short-term administration increases extracellular 5-HT in rat brain Vortioxetine s multimodal activity makes it a valuable tool for research into serotonergic modulation and antidepressant mechanisms
Medchemexpress LLC Vortioxetine | 508233-74-7 | C18H22N2S | 25 MG
Vortioxetine is an analytical standard and multimodal serotonergic agent. It functions as an antagonist of 5-HT3A and 5-HT7 receptors, an inhibitor of serotonin transporter (SERT), an agonist of 5-HT1A receptors, and a partial agonist of 5-HT1B receptors. This compound is intended for research and analytical applications, serving as a reference standard for various assay purposes.
- Antagonist of 5-HT3A and 5-HT7 receptors
- Inhibitor of serotonin transporter (SERT)
- Agonist of 5-HT1A receptors
- Partial agonist of 5-HT1B receptors
- Used as an analytical reference standard
- Suitable for qualitative, quantitative, and methodological research experiments (HPLC, GC, MS)
Medchemexpress LLC Vortioxetine | 508233-74-7 | C18H22N2S | 1 G
Vortioxetine (Lu AA 21004) is a multimodal serotonergic agent that acts as an antagonist of 5-HT3A and 5-HT7 receptors and an inhibitor of the serotonin transporter (SERT). It also functions as a 5-HT1A agonist and a partial agonist of 5-HT1B.
- Antagonist of 5-HT3A and 5-HT7 receptors
- Inhibitor of serotonin transporter (SERT)
- Agonist of 5-HT1A receptor
- Partial agonist of 5-HT1B receptor
- Intended for research use only
- Does not cause cognitive or psychomotor impairment
Medchemexpress LLC Eckol 1mg | 88798-74-7 | 1 MG
Eckol is a naturally occurring phlorotannin isolated from brown algae, used in biochemical research as a monoamine oxidase (MAO) inhibitor and for studies of antiviral and antiallergic activity. It is supplied as a white to off-white solid and is provided for research use only (not for human or clinical use).
- High analytical purity suitable for research applications.
- Reported hMAO-A and hMAO-B inhibitory activity (IC50 ≈ 7.20 μM and 83.44 μM).
- Well characterized chemical identity: C18H12O9, MW 372.28 g·mol⁻1.
- Solid, white to off-white appearance for easy handling.
- Recommended low-temperature, sealed storage to maintain stability.
- Intended for in vitro research and biochemical studies.
Medchemexpress LLC FT709 | 2413991-74-7 | C23H22N4O7S | 1 MG
FT709 is a potent and selective USP9X inhibitor with an IC50 of 82 nM. USP9X has been linked to various cellular functions including centrosome function, chromosome alignment during mitosis, EGF receptor degradation, chemo-sensitization, and circadian rhythms. This product is for research use only.
- Potent and selective USP9X inhibitor
- IC50 of 82 nM
- Linked to centrosome function
- Linked to chromosome alignment during mitosis
- Linked to EGF receptor degradation
- Linked to chemo-sensitization
- Linked to circadian rhythms
- Decreases levels of ZNF598 (ubiquitin E3 ligase)
- Decreases levels of centrosomal protein CEP55 in HCT116 cells
Medchemexpress LLC IRAK4-IN-7 | 1801343-74-7 | 99.4% | 417.42 | 100 UG
IRAK4-IN-7 is a selective, potent, and orally active interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, extracted from patent WO2015104688 (example 1). It has the potential for cancer and inflammatory diseases treatment. For research use only, not for sale to patients.
- Selective, potent, and orally active inhibitor.
- Potential for cancer and inflammatory diseases treatment.
- Has anti-cancer and anti-inflammatory activities.
Medchemexpress LLC IRAK4-IN-7 | 1801343-74-7 | 99.4% | 417.42 | 200 UG
IRAK4-IN-7 is a selective, potent, and orally active interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor. It is extracted from patent WO2015104688 (example 1) and holds potential for the treatment of cancer and inflammatory diseases. It exhibits anti-cancer and anti-inflammatory activities, making it suitable for research in these therapeutic areas.
- Selective and potent inhibitor
- Orally active
- Potential for cancer treatment
- Potential for inflammatory diseases treatment
- Suitable for in vivo and in vitro research
Medchemexpress LLC IRAK4-IN-7 | 1801343-74-7 | 99.36% | 417.42 | 500 UG
IRAK4-IN-7 is a selective, potent, and orally active interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, extracted from patent WO2015104688 (example 1). It has potential for cancer and inflammatory disease treatment. It exhibits anti-cancer and anti-inflammatory activities.
- Selective and potent IRAK4 inhibitor
- Orally active
- Potential for cancer treatment
- Potential for inflammatory disease treatment
- Exhibits anti-cancer activities
- Exhibits anti-inflammatory activities
Medchemexpress LLC Ft709 | 2413991-74-7 | 99.8% | C23H22N4O7S | 10MG
FT709 is a potent, selective small-molecule inhibitor of the deubiquitinase USP9X (IC50 ≈ 82 nM), intended for biochemical and cell-based research to probe ubiquitin-dependent pathways and mitotic regulation. Supplied as a dry solid and as DMSO solution formats for flexible use in laboratory assays.
- Potent, selective inhibition of USP9X (IC50 ≈ 82 nM).
- Suitable for biochemical and cell-based assays.
- Available as dry solid and DMSO solution for flexible dosing.
- High reported purity for research applications.
- Useful for studying mitosis and ubiquitin-dependent signaling.
Medchemexpress LLC Salsolidine | 5784-74-7 | 97.4% | 207.27 | 50 MG
Salsolidine is a tetrahydroisoquinoline alkaloid that acts as a stereoselective competitive MAO A inhibitor. It is intended for research use only.
- Tetrahydroisoquinoline alkaloid
- Stereoselective competitive MAO A inhibitor
- R-salsolidine is more active against MAO A than S-salsolidine (Ki=6 μM and 186 μM, respectively)
- Weakly inhibits binding of δ-receptor (Ki >100 μM)
- Potential for inhibiting Acetylcholinesterase and butyrylcholinesterase
- Appears as a solid
- Color is light yellow to brown
- Initial source is animals (bovine liver)
Medchemexpress LLC FT709 | 2413991-74-7 | 99.8% | C23H22N4O7S | 1 ML
FT709 is a potent and selective inhibitor of USP9X, exhibiting an IC50 of 82 nM. USP9X has been associated with various cellular functions, including centrosome function, chromosome alignment during mitosis, EGF receptor degradation, chemo-sensitization, and circadian rhythms. This product is for research use only.
- Potent and selective USP9X inhibitor
- Exhibits an IC50 of 82 nM
- Associated with centrosome function
- Associated with chromosome alignment during mitosis
- Associated with EGF receptor degradation
- Associated with chemo-sensitization
- Associated with circadian rhythms
- Decreases levels of ZNF598 (ubiquitin E3 ligase) and centrosomal protein CEP55 in HCT116 cells
- Suitable for research applications